New drug cocktail shows promise for tough pancreatic cancer

NCT ID NCT04752696

Completed Disease control Sponsor: Cardiff Oncology Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested a new drug called onvansertib combined with standard chemotherapy for people with metastatic pancreatic cancer that had already been treated once. The study enrolled 41 adults and measured how many patients' tumors shrank. The goal is to find a better second-line treatment for this aggressive cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: onvansertib (a targeted cancer drug) combined with chemotherapy (nanoliposomal irinotecan, leucovorin, and fluorouracil)
What this could lead to: If successful, this combination could offer a new second-line treatment option for people with metastatic pancreatic cancer who have already tried one chemotherapy.
What could go wrong: This is a small, early-phase trial (Phase 2) with only 41 participants. The results may not apply to all patients, and the combination may cause significant side effects. It is not yet proven to extend survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Locations

Inova Schar Cancer Institute

Fairfax, Virginia, 22031, United States
Mayo Clinic Jacksonville

Jacksonville, Florida, 32224, United States
Mayo Clinic Phoenix

Phoenix, Arizona, 85054, United States
Mayo Clinic Rochester

Rochester, Minnesota, 55905, United States
University of Kansas Medical Center

Westwood, Kansas, 66205, United States
University of Nebraska Medical Center

Omaha, Nebraska, 68198, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.